Australian equity markets faced dual shocks Friday as biotech Immutep Ltd. collapsed 93% after halting lung cancer drug trials, wiping out A$582 million ($412 million) in market value. Northern Star Resources Ltd. simultaneously plunged to six-year lows following guidance cuts due to processing mill problems.
Immutep's trial suspension represents a critical setback for the clinical-stage company and its backers, including Sydney hedge fund Regal Partners Ltd., which had significant exposure to the biotech. Northern Star's operational challenges at its processing facilities forced the gold miner to reduce output expectations, highlighting infrastructure vulnerabilities in Australia's mining sector.
The dual collapse sent ripples through Australian small-cap and resources indices, with biotech and gold mining sectors leading declines. Healthcare and materials stocks faced broader selling pressure as investors reassessed exposure to operational and clinical risks in these volatile sectors.
Both companies now face critical restructuring periods, with Immutep needing to pivot its drug development strategy while Northern Star must resolve mill operations to restore production targets.